Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment

Metastatic castrate-resistant prostate cancer (CRPC) remains uncurable and novel therapies are needed to better treat patients. Aberrant Fibroblast Growth Factor Receptor (FGFR) signaling has been implicated in advanced prostate cancer (PCa), and FGFR1 is suggested to be a promising therapeutic targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Juyeon, Meyer, April N., Haas, Martin, Donoghue, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800776/
https://www.ncbi.nlm.nih.gov/pubmed/33456711
http://dx.doi.org/10.18632/oncotarget.27859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800776/
https://www.ncbi.nlm.nih.gov/pubmed/33456711
http://dx.doi.org/10.18632/oncotarget.27859

Ejemplares similares